Kozminski University focuses on education based on reliable scientific knowledge, passed on in a modern way, by a properly prepared, experienced team of scientists, business practitioners and entrepreneurs. KU sees his development in the internationalization of the educational process, and international cooperation is one of the elements of the university's success.
The „WE! are Clinical Research" Movement was created with the intention of introducing international contribution to the discussion about clinical trials. In its assumptions, it wants to connect representatives of various environments, industries, and nationalities in order to exchange experiences and build wider cooperation and understanding of the goals of our activities. Therefore, on behalf of the Kozminski University and ours, we invite you to the next Webinar of the „WE! are Clinical Research” movement.
Rare diseases in the clinical trials
Do orphan diseases really affect us so rarely? What problems do patients and their families face? What are the challenges for the team that conducts clinical trials in the indications of rare diseases?
Our guests Magdalena Margasińska-Brach and Daniel Lewi will try to answer these and many other questions during the next webinar organized by the WE! are the Clinical Trials movement.
Time and place: June 24th, 2021 at 6:00 PM CET, online – Zoom meeting
The webinar will be conducted in Polish and English. Simultaneous translation will be available thanks to the support of the British Embassy in Poland. Technical issues will be communicated to those registered with a link to the event.
We act and support!
Every activity of the "WE! are the Clinical Research" will be associated with the support of the Kozminski Foundation, whose goals include activities for the development of science, education and upbringing and supporting gifted youth. The cost of participation in the Webinar is PLN 50 and the entire amount collected is allocated to the activities of the Kozminski Foundation.
See you at the webinar!
A graduate of the Warsaw University (Faculty of Chemistry), the Medical University of Gdańsk and the Gdańsk Foundation for Management Development (Clinical Research Management).
For 21 years associated with the pharmaceutical industry, and 19 years within clinical research. Responsible for the management, organization and conduct of clinical trials in different specialist, managerial and director positions in pharmaceutical and global CRO companies. Currently, for over four years professionally associated with Pharmaceutical Product Development (PPD), where as a Project Director and Oversight Director is responsible for managing global programs and clinical projects as well as relationships with key clients.
Perfectly understands the clinical research field. Has almost two decades of extensive professional experience in managing multidisciplinary research teams in various therapeutic indications. Subject Matter Expert in the field of pediatric research and rare diseases. Currently, co-creates a global training program for pediatric and rare disease studies. Is passionate about modern and innovative methods of patient recruitment and cooperation with global patient organizations. An Expert of the Medical Research Agency in Poland.
A long-time educator in the field related to the management of clinical trials, recruitment strategies, clinical trials in pediatrics and rare diseases. Speaker at local and international industry conferences and courses. Member of GCP PL, ACRP, PMI and PIPMG.
Like Steve Jobs believes that "The only way to do a good job is to love what you do"
Dan Lewi is Head of Business Development and Patient Advocacy at Pulse Infoframe, is the founder of the rare disease charity The Cure & Action for Tay-Sachs (CATS) Foundation in the UK and is also the chairman of the European Tay-Sachs and Sandhoff Charity Consortium (ETSCC). His unique experience in the MedTech sector is combined with over 10 years in the advocacy sector meaning that Dan is fully aware of the patient voice and is able to always put them at the forefront of the discussion in relation to the development of clinical studies.
Having set up The CATS Foundation in 2011 after his daughter Amélie was diagnosed with Tay-Sachs, Dan has been instrumental in driving forward the research for the disease. In 10 years, he has helped bring various gene therapy, drug repurposing and small molecule programmes for the disease into the clinic.